Quick Update for VTRS Investors

Today we're going to take a closer look at large-cap Health Care company Viatris, whose shares are currently trading at $10.09. We've been asking ourselves whether the company is under or over valued at today's prices... let's perform a brief value analysis to find out!

The Market May Be Undervaluing Viatris's Assets and Equity:

Viatris Inc. operates as a healthcare company worldwide. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) ratio of 4.16. In contrast, Viatris has a trailing 12 month P/E ratio of 6.9 and a P/B ratio of 0.58.

When we divide Viatris's P/E ratio by its expected EPS growth rate of the next five years, we obtain its PEG ratio of -1.73. Since it's negative, the company has negative growth expectations, and most investors will probably avoid the stock unless it has an exceptionally low P/E and P/B ratio.

The Business Has Weak Operating Margins:

2021-02-08 2022-02-28 2023-02-27
Revenue (MM) $11,946 $17,886 $16,263
Gross Margins 32.0% 31.0% 40.0%
Operating Margins -1% 2% 10%
Net Margins -6.0% -7.0% 13.0%
Net Income (MM) -$670 -$1,269 $2,079
Net Interest Expense (MM) -$498 -$636 -$592
Depreciation & Amort. (MM) -$2,216 -$4,506 -$3,028
Earnings Per Share -$1.11 -$1.05 $1.71
EPS Growth n/a 5.41% 262.86%
Diluted Shares (MM) 601 1,213 1,217
Free Cash Flow (MM) $1,453 $3,359 $1,395
Capital Expenditures (MM) -$221 -$342 $1,558
Net Current Assets (MM) -$25,731 -$23,447 -$18,314
Long Term Debt (MM) $22,429 $19,717 $18,015
Net Debt / EBITDA 11.6 4.6 3.85

Viatris has slimmer gross margins than its peers, weak operating margins with a positive growth rate, and a highly leveraged balance sheet. On the other hand, the company has a strong EPS growth trend working in its favor. Furthermore, Viatris has weak revenue growth and a flat capital expenditure trend, irregular cash flows, and a decent current ratio.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS